• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Psychiatry

Deep brain stimulation may improve clinical outcomes in individuals with treatment resistant depression  

byKiera LiblikandAvneesh Bhangu
November 15, 2021
in Psychiatry, Wellness
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this clinical trial, deep brain stimulation (DBS) showed clinical benefit in patients with treatment resistant depression (TRD).

2. Improvement was sustained for over 10 years in half of patients who completed follow-up.

Evidence Rating Level: 3 (Average)

Major depressive disorder is refractory to treatment impacts in over a third of patients. Deep brain stimulation (DBS) has been used to improve symptoms in those with tremors but shows potential benefit for those with treatment resistant depression (TRD). It is not known whether improvement in these patients is sustained over an extended follow-up period.

The present clinical trial measured psychiatric function in a group of patients who received TRD. Patients were included who were diagnosed with severe TRD and had previously failed at least 4 trials of therapeutics. Outcomes were measured with the Montgomery-Šsberg Depression Rating Scale (MADRS) and adverse events were recorded using retrospective chart review. Follow-up occurred annually up to 10 years after baseline assessment.

In total, 8 patients were included and 6 completed the entirety of follow-up. At 10 years, 50% of participants had sustained clinically significant improvement of symptoms whereas 25% of participants were in full remission from TRD. One patient discontinued DBS due to perceived lack of improvement, and another committed suicide after DBS was stopped due to recurrent mania. This study was limited in that it included a small sample size and lack of control group. Therefore, these results cannot be reliably applied to the general population. Nonetheless, this study suggests that DBS may reduce symptoms in patients with TRD, and sustain improvement for up to 10 years. Future studies would be necessary to include a larger sample size and determine optimal stimulation requirements for patients with TRD.

RELATED REPORTS

Federal Drug Administration approves Alzheimer’s blood test for use in primary care

Self-Help App for Depression in People With Intellectual Disabilities: A Randomized Clinical Trial

2 Minute Medicine Rewind October 13, 2025

Click to read the study in The Journal of Clinical Psychiatry

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: deep brain stimulationdepressionmaniamental healthtreatment resistant depressionwellness
Previous Post

Maternal genetic risk of hypertension associated with reduced placental weight

Next Post

Adjuvant gefitinib compared to chemotherapy after lung cancer resection did not improve survival

RelatedReports

FDA-regulated clinical trials rarely report violations
The Scan by 2 Minute Medicine®

Federal Drug Administration approves Alzheimer’s blood test for use in primary care

October 22, 2025
Shared decision-making tool for antidepressants improves patient and physician satisfaction
Chronic Disease

Self-Help App for Depression in People With Intellectual Disabilities: A Randomized Clinical Trial

October 16, 2025
Weekly Rewinds

2 Minute Medicine Rewind October 13, 2025

October 13, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Obstetrics

The Scan by 2 Minute Medicine®: Leucovorin autism update, Oura Ring FDA scrutiny, Lilly oral GLP-1 trial, and Florida vaccine mandate repeal

September 25, 2025
Next Post
Patient Basics: Lung Cancer Overview

Adjuvant gefitinib compared to chemotherapy after lung cancer resection did not improve survival

Compliance-linked incentives increase infant immunizations rates in rural India

Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer

Quick Take: Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery
  • Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia
  • Effect of Intensive Blood Pressure Lowering Treatment on Retinal Microvasculature: Secondary Analysis From ESPRIT
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.